Selecta Biosciences, Inc.
SELB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.03 | -0.03 | 0.00 |
| FCF Yield | -116.03% | -23.36% | -4.59% | -5.74% |
| EV / EBITDA | 5.94 | 0.00 | 2.37 | 0.00 |
| Quality | ||||
| ROIC | -5.73% | 0.00% | 10.29% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 88.16% | 0.00% |
| Cash Conversion Ratio | 0.43 | -1.10 | 1.30 | -0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -40.76% | -42.99% | -38.83% | -32.41% |
| Free Cash Flow Growth | 16.82% | -409.12% | 20.01% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 6.74 | 0.00 | 4.95 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | -17.68 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 106.91 | 144.41 | -6.63 | 1,350.93 |